Zobrazeno 91 - 100
of 21 623
pro vyhledávání: ''
Publikováno v:
Anti-Cancer Drugs. 32:1127-1130
Avapritinib is a tyrosine kinase inhibitor currently being investigated on clinical trials for the treatment of unresectable or metastatic gastrointestinal stromal tumour (GIST). It has been recently approved by the Food and Drug Administration and t
Autor:
Hiroomi Ogawa, Makoto Sohda, Kengo Kuriyama, Takayoshi Watanabe, Yasunari Ubukata, Ken Shirabe, Takehiko Yokobori, Hiroshi Saeki, Makoto Sakai, Arisa Yamaguchi, Hideyuki Saito, Nobuhiro Nakazawa, Akihiko Sano
Publikováno v:
Anticancer Research. 41:3925-3931
Background/aim This study clarified the predictive impact of serum biomarkers on therapeutic sensitivity to nivolumab in patients with gastric cancer (GC). Patients and methods The outcomes of 27 patients who received nivolumab to treat postoperative
Autor:
Yuta Mukae, Tsuyoshi Matsuda, Yuichiro Nakamura, Hidenori Ito, Hideki Sakai, Yasuyoshi Miyata, Tomohiro Matsuo, Kaname Ohyama, Nozomi Aibara, Kyohei Araki
Publikováno v:
Anticancer Research. 41:3815-3823
Background/aim A previous report showed that immune complex-ceruloplasmin (CP) in urine is associated with carcinogenesis and malignant behavior in bladder cancer (BC). We investigated the pathological significance and prognostic roles of urine and t
Autor:
Hiroya Takeuchi, Takafumi Kawamura, Kazuya Shinmura, Yoshihiro Hiramatsu, Mayu Sakata, Hirotoshi Kikuchi, Kakeru Torii, Kiyotaka Kurachi, Yoshifumi Morita, Atsuko Fukazawa, Moriya Iwaizumi, Kyota Tatsuta, Toshiya Akai
Publikováno v:
Clinical Journal of Gastroenterology. 14:1448-1452
In mismatch repair (MMR) immunohistochemistry, four MMR proteins’ staining pattern reveals which particular gene may be defective. However, in the null phenotype, four MMR proteins are lost; consequently, it will be challenging to assume the target
Autor:
Gina Klee, Patrick Terheyden, Jonas K. Kurzhals, Victoria Hagelstein, Detlef Zillikens, Ewan A. Langan, Andreas Recke
Publikováno v:
Melanoma Research. 31:464-471
Combined immunotherapy is associated with a significant risk of severe and potentially fatal immune-related adverse events (irAEs). Therefore, we retrospectively analyzed the side profile and efficacy of low-dose ipilimumab (1 mg/kg, IPI1) combined w
Autor:
Bulent Koca, Murat Yildirim
Publikováno v:
Cancer Biomarkers. 31:409-417
BACKGROUND: Lymphocyte-to-C-reactive protein ratio (LCR) has been used as a post-surgical prognostic biomarker in patients with gastric and colorectal cancer. However, its relationship with early postoperative complications in these patients is unkno
Autor:
Ririnoi Honma, Watarui Yasui, Shoichii Ukai, Kenji Harada, Yusukei Yamamoto, Kazuakii Tanabe, Yukii Takemoto, Daikii Taniyama, Quoc Thangi Pham, Tsuyoshii Takashima, Hiroshii Ota, Ryotai Maruyama, Hidekii Ohdan, Naoyai Sakamoto
Publikováno v:
Gastric Cancer. 24:1264-1277
The attainment of drug resistance in gastric cancer (GC) is a problematic issue. Although many studies have shown that cancer stem cells (CSCs) play an important role in the acquisition of drug resistance, there is no clinically available biomarker f
Autor:
Cristiana Sessa, Monia Guidi, Laura Moser, Eleftherios P. Samartzis, Mariarosa Pascale, Ilaria Colombo, Tatiana Terrot, Milo Frattini, Simone Brandt, Anastasios Stathis, Sheila Gaggetta, Sofia Genta, Federica Martorana
Publikováno v:
Clinical Cancer Research. 27:5012-5019
Purpose: This phase I study evaluated safety, tolerability, pharmacokinetics, and preliminary activity of the PI3K/mTORC1/2 dual inhibitor gedatolisib combined with carboplatin and paclitaxel. Patients and Methods: Patients with advanced solid tumors
Autor:
Koichi Takahashi, Naval Daver, Sanam Loghavi, Yesid Alvarado, Rasoul Pourebrahim, Abhishek Maiti, Tapan M. Kadia, Hagop M. Kantarjian, Musa Yilmaz, Nicholas J. Short, Kunhwa Kim, Courtney D. DiNardo, Maro Ohanian, Farhad Ravandi, Koji Sasaki, Marina Konopleva, Ken Furudate, Guilin Tang, Caitlin R. Rausch
Publikováno v:
Cancer. 127:3772-3781
BACKGROUND TP53 mutation (TP53mut ) confers an adverse prognosis in acute myeloid leukemia (AML). Venetoclax with hypomethylating agents is a current standard for older patients; however, recent reports suggest that TP53mut confers resistance to vene
Autor:
Gang An, Chenmu Du, Shu Cheng, Jianfeng Zhou, Binghao Wu, Haiyi Guo, Lingzhi Yan, Liye Zhong, Yiling Yu, Jie Jin, Liping Xie, Jinhua Zhong, Daobin Zhou, Jianyong Li, Keshu Zhou, Lugui Qiu
Publikováno v:
Clinical Cancer Research. 27:5492-5501
Purpose: Although Bruton tyrosine kinase (BTK) inhibitors have demonstrated promising efficacy in patients with Waldenström macroglobulinemia (WM), data in Asian populations are scarce. This trial is the first to investigate the effect of a BTK inhi